Statin-related adverse drug reactions in UK primary care consultations: A retrospective cohort study to evaluate the risk of cardiovascular events and all-cause mortality.

Autor: Insani WN; Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.; Department of Pharmacology and Clinical Pharmacy, Centre of Excellence for Pharmaceutical Care Innovation, Padjadjaran University, Bandung, Indonesia., Whittlesea C; Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK., Ju C; Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK., Man KKC; Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.; Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, University of Hong Kong, Hong Kong Special Administrative Region, China.; Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong Special Administrative Region, China., Alwafi H; Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.; Faculty of Medicine, Umm Al Qura University, Mecca, Saudi Arabia., Alsharif A; Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.; Department of Pharmacy Practice, Faculty of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia., Chapman S; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK., Wei L; Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.; Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong Special Administrative Region, China.
Jazyk: angličtina
Zdroj: British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Nov; Vol. 88 (11), pp. 4902-4914. Date of Electronic Publication: 2022 Jun 23.
DOI: 10.1111/bcp.15438
Abstrakt: Aims: To investigate the risk of cardiovascular disease (CVD) events and all-cause mortality in patients with statin-related adverse drug reaction (ADR) consultation in primary care and examine whether different treatments following the ADR affect subsequent outcomes.
Methods: This was a retrospective cohort study of statin users between 2004 and 2019 using IQVIA Medical Research Data (formally known as the THIN database). Patients with statin-related ADR consultation were matched by propensity score (1:1) to statin users without ADR consultation based on demographics, comorbidities and concomitant medication. Cox proportional hazard regression was used to compare the risk of subsequent CVD event and all-cause mortality, stratified by history of CVD. In the secondary analysis among patients with statin-related ADR, treatment changes within a 1-year period following the ADR were examined and the outcomes were compared between different treatment groups.
Results: Among 1 564 687 statin users, 19 035 (1.22%) had a statin-related ADR consultation in primary care. The mean (standard deviation) follow-up time was 6.32 (3.74) years and 5.31 (3.83) years for CVD primary and secondary prevention cohorts, respectively. Statin-related ADR consultation was associated with subsequent CVD events in both cohorts (adjusted hazard ratio [HR] of 1.39 [95% CI 1.23, 1.57] and 1.34 [95% CI 1.25,1.42], respectively). In the secondary analysis among patients with statin-related ADR consultation, we found that (i) continued statin prescription or combination of any statin with additional lipid-lowering treatment (LLT) and (ii) other LLT only were associated with lower risks of CVD event (adjusted HR 0.71 [95% CI 0.64, 0.78] and 0.75 [95% CI 0.62, 0.92], respectively) and all-cause mortality (adjusted HR 0.46 [95% CI 0.42, 0.50] and 0.52 [95% CI, 0.43, 0.64], respectively), compared to discontinuation of all LLT.
Conclusion: Statin-related ADR was associated with an increased risk of subsequent CVD event, indicating that these patients should be monitored more closely. Continued lipid-lowering medication is of importance to protect against CVD events and mortality.
(© 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)
Databáze: MEDLINE
Externí odkaz: